The PHF6 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the PHF6 gene in the human Raji B lymphocyte line. This heterogeneous loss-of-function model is generated by introducing CRISPR/Cas9-mediated gene disruptions across a bulk cell population, providing a diverse pool that avoids clonal artifacts. It is designed for functional studies of PHF6-dependent chromatin regulation in lymphocyte biology. By targeting PHF6, which encodes a chromatin-associated adaptor, this polyclonal knockout system enables precise interrogation of its biological roles.
The Raji cell line is a well-characterized human B lymphocyte model derived from Burkitt??s lymphoma, EBV-positive and growing in suspension. Widely used in immunology, cancer, and epigenetic research, Raji cells offer a relevant system for studying chromatin modifiers in lymphomagenesis. Their EBV-positive status and expression of mature B-cell markers provide a physiologically relevant background. Their established molecular profile facilitates dissection of how PHF6 loss alters B-cell function and disease phenotypes.
PHF6 is a chromatin-associated protein that serves as an adaptor for the NuRD nucleosome remodeling and deacetylase complex. It interacts with NuRD components CHD4, HDAC1, HDAC2, MTA2, RBBP4, RBBP7, and UHRF1 to catalyze histone H3 deacetylation and transcriptional repression. Regulated by NOTCH1 signaling and other transcriptional inputs, PHF6 controls hematopoietic gene expression and NuRD target genes. This places PHF6 at a central node of chromatin organization, hematopoietic development, and tumor suppression; its inactivation is associated with T-cell acute lymphoblastic leukemia, acute myeloid leukemia, and B?rjeson-Forssman-Lehmann syndrome.
In Raji B cells, PHF6 knockout is expected to disrupt NuRD-mediated chromatin regulation, altering genes governing proliferation, apoptosis, and differentiation. This model enables investigation of PHF6??s tumor-suppressive roles specifically in the B-cell lineage, complementing T-cell and myeloid studies. The polyclonal pool captures phenotypic heterogeneity, making it valuable for drug sensitivity screening and resistance studies in lymphoma. This model thus serves as a valuable tool for dissecting the epigenetic and transcriptional networks underlying B-cell malignancies.
Applications include functional characterization of PHF6 in B lymphocytes, chromatin remodeling research, epigenetic drug screening, and transcriptional regulation studies. Assays such as Western blotting, RT-qPCR, RNA-seq, ChIP-qPCR, flow cytometry, co-immunoprecipitation, apoptosis, and drug sensitivity assays are applicable. These cells are also suitable for co-culture experiments and high-throughput screening platforms. For further information, please contact Ascent Research.
